News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
The New Cough Management Feature is based on decades of scientific evidence and is expected to empower millions of coughers with the tools to help manage Chronic Cough
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough
Wilmington, Del., Sep 9, 2024 -- CoughPro, the global leader in consumer cough tracking and monitoring, proudly announces the launch of its pioneering Cough Management feature, marking a global first in digital wellness. Cough Management is now available within the CoughPro app, offering science-based, actionable lifestyle and behavioral content for individuals struggling with chronic cough conditions.
Powered by the principles of Behavioral Cough Suppression and Hyfe’s state-of-the-art cough detection, CoughPro’s Cough Management leverages cutting-edge AI technology to offer users a science-backed approach to taking control of their cough. As the go-to tool for thousands of users worldwide, CoughPro continues to set the standard for cough monitoring in a wellness setting, now expanding its scope to include support for daily Cough Management.
Chronic cough, particularly refractory or unexplained chronic cough, affects about 1 in 10 people in the United States1. CoughPro’s Cough Management feature provides these individuals with a way to live better with their cough, integrating evidence-based techniques2 used by speech and language pathologists.
CoughPro’s Cough Management Tool introduces users to the “3 Rs” framework of Cough Management:
Users benefit from educational content, interactive lessons, and practical exercises designed to help them better understand their cough and take proactive steps to manage it. The feature includes audio guides, video demonstrations, and feedback mechanisms to ensure users master the techniques.
We are excited to give our users the means to take action on their chronic cough. Our mission has always been to empower individuals with tools they need to improve their wellbeing. Cough Management represents a significant step forward in Hyfe’s commitment to bettering the lives of people with chronic cough.
Reid Moorsmith
Hyfe’s CXO
CoughPro is the leading consumer app for cough tracking and monitoring, using state-of-the-art AI technology developed by Hyfe. With thousands of users worldwide, CoughPro is committed to providing accurate and reliable cough data, helping users and healthcare professionals better understand and manage cough conditions.
For more information, visit www.coughpro.com or contact press@coughpro.com.
***
CoughPro – and the Cough Management feature – is currently available as a wellness app and is not intended to diagnose, treat, cure, or prevent any disease. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA) as a medical device or treatment. Users are advised to consult with a healthcare professional before making any medical decisions about their cough.
References:
1 The exact prevalence of chronic cough ranges in literature anywhere between 5% and 18%. This publication puts the United States’ number at 9.6%.
2 Evidence for the effectiveness of cough suppression therapy: RCT1, RCT2 and RCT3 on combination therapy.
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.